

Inter-assay precision of clonogenic assays for radiosensitivity in cancer cell line A549

Endang Nuryadi^{1,2,*}, Tiara Bunga Mayang Permata^{1,2,*}, Shuichiro Komatsu¹, Takahiro Oike¹ and Takashi Nakano¹

¹Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan

²Department of Radiotherapy, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia

*These authors contributed equally to this work

Correspondence to: Takahiro Oike, **email:** oiketakahiro@gmail.com

Keywords: clonogenic assay; radiosensitivity; cancer cell; meta-analysis; precision medicine

Received: December 13, 2017

Accepted: January 30, 2018

Published: February 07, 2018

Copyright: Nuryadi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Clonogenic assays are the gold standard for determining radiosensitivity, which governs tumor response to radiation therapy. Although multiple studies of clonogenic assays on cancer cell lines have been published, the robustness of this technique has not been examined by comparative analysis of data from different studies. To address this issue, we investigated the inter-assay precision of clonogenic assays by analyzing in-house and published data on A549, a cell line frequently studied in this context. The coefficients of variation for SF2, the surviving fraction after 2 Gy irradiation, and D10, the radiation dose that reduces survival to 10%, were below 30% for both in-house data obtained from 20 independent experiments performed under consistent experimental settings (i.e., radiation type, dose rate, and timing of cell seeding) and data collected from 192 publications using diverse experimental settings. Multivariate analyses of the published data revealed that timing of cell seeding significantly affected SF2. These data indicate that SF2 and D10 of clonogenic assay have acceptable inter-assay precision, and that timing of cell seeding influences the inter-assay precision of SF2. These results provide a rationale for combined analysis of published clonogenic assay data, which may help to discover robust biological properties associated with tumor radiosensitivity.

INTRODUCTION

Clonogenic assays are the gold standard for determining reproductive cell death induced by ionizing radiation (IR) [1]. Multiple studies show that cellular radiosensitivity, as determined by clonogenic assay in cancer cell lines, is relevant to the tumor response to radiation therapy [2]. On the other hand, recent advances in computer science, including machine learning, and in omics technologies, such as next-generation sequencing, enable us to conduct high-throughput analysis of big data with the goal of discovering biomarkers and therapeutic targets useful for precision cancer medicine [3]. Multiple data resources, such as the Cancer Cell Line Encyclopedia (CCLE) and Catalogue of Somatic Mutations in Cancer

[4, 5], provide extensive omics information about cancer cell lines, including mutation and mRNA expression profiles. Similarly, an enormous number of publications report radiosensitivity of cancer cell lines as assessed by clonogenic assays. Bioinformatics analyses using the available clonogenic assay and omics data in combination have significant potential for the discovery of biological properties associated with radiosensitivity, which will be useful for prediction of tumor responses to radiation therapy. However, the robustness of clonogenic assays has not been examined by comparative analysis of data from different studies.

To address this issue, we evaluated the inter-assay precision of clonogenic assay by analyzing in-house and published data on A549, a cell line frequently studied

using this method. Using in-house data acquired from 20 independent *in vitro* experiments and data acquired from 192 publications identified by a comprehensive literature search, we analyzed the coefficient of variation (CV) of clonogenic survival and the influence of experimental settings on assay results.

RESULTS

Data acquisition from the literature

To analyze inter-assay precision of clonogenic assays, we first conducted a literature search to compile data obtained using these methods. We sought to acquire the greatest quantity of data on clonogenic assays from a specific human cancer cell line treated with X-rays or γ -rays. To this end, we performed a comprehensive literature search for 1039 human cancer cell lines registered in CCLE (see *Literature search* in MATERIALS AND METHODS for details). We found that the lung cancer cell line A549 is most frequently used in studies of sensitivity to X-rays or γ -rays using clonogenic assays, and has been described in 192 papers. From these papers, we extracted the values of SF₂, SF₄, SF₆, SF₈, D₁₀, and D₅₀ as endpoints for clonogenic survival (see *Acquisition of clonogenic survival data from the literature* in MATERIALS AND METHODS for details). In addition, we extracted information regarding experimental settings that can affect clonogenic survival, including radiation type, dose rate, and timing of cell seeding [1]. The contents of the dataset are summarized in Figure 1. The entire dataset is described in Supplementary Table 1.

Data acquisition from *in vitro* experiments

Next, we acquired in-house data from clonogenic assays on IR-treated A549 cells. We performed 20 independent experiments using consistent experimental settings (radiation type: X-rays, dose rate: 1.14 Gy/min,

and timing of cell seeding: before irradiation), and acquired the values of SF₂, SF₄, SF₆, SF₈, D₁₀, and D₅₀ (Figure 2, Supplementary Table 2).

Analysis of inter-assay precision for clonogenic survival endpoints

To investigate the inter-assay precision of clonogenic assays, we examined the CV values of the clonogenic survival endpoints, following the recommendation from the Food and Drug Administration (FDA) that a CV of lower than 30% is acceptable for assessment of potential biomarkers [6, 7]. For the in-house data obtained using consistent experimental settings, the CV values were below 30% for SF₂, D₁₀, and D₅₀ (Figure 3). For published data obtained using experimental settings comparable to those of our in-house experiments (i.e., radiation type: X-rays, dose rate: 1.14 ± 0.5 Gy/min, timing of cell seeding: before irradiation), CV values of clonogenic survival endpoints were also below 30% for SF₂, D₁₀, and D₅₀ (Figure 3), validating the analysis of the in-house experiments. These data indicate that the clonogenic assays have acceptable inter-assay precision as a measure of radiosensitivity when experimental settings are consistent, and when SF₂, D₁₀, and D₅₀ are used as endpoints.

To investigate whether clonogenic assays have acceptable inter-assay precision under diverse experimental settings, as is the case for data obtained by different laboratories and clinics, we examined CV values of clonogenic survival endpoints for all publications without restricting the experimental settings. Interestingly, CV values of SF₂ and D₁₀ remained below 30%, comparable to those of the in-house experiments (Figure 3). Taken together, these data indicate that clonogenic assays have acceptable inter-assay precision as a measure for radiosensitivity, regardless of experimental settings related to radiation type, dose rate, and timing of cell seeding, when SF₂ and D₁₀ are used as endpoints.




Figure 1: Summary of clonogenic assay data acquired from publications. (A) Radiation type ($n = 188$). (B) Dose rate ($n = 144$). (C) Timing of cell seeding ($n = 192$). (D) SF₂ ($n = 179$), SF₄ ($n = 156$), SF₆ ($n = 136$), and SF₈ ($n = 92$). (E) D₁₀ ($n = 79$) and D₅₀ ($n = 79$).

Finally, we investigated the influence of differences in experimental settings on clonogenic survival, using all the published data. Univariate analysis revealed that radiation type (X-rays or γ -rays), dose rate, and timing of cell seeding (before or after irradiation) did not have a significant impact on SF₂, SF₄, SF₆, SF₈, D₁₀, or D₅₀ (Table 1), although we did observe a trend toward higher SF₂ values for cells

seeded before irradiation compared with those seeded after irradiation ($P = 0.06$). Consistent with this, multivariate analysis revealed that the timing of cell seeding had a significant impact on SF₂ ($P = 0.04$), but we observed no significant impact of these experimental settings on any other clonogenic survival endpoints tested (Table 2). These data suggest that the timing of cell seeding influences SF₂.




Figure 2: Summary of clonogenic survival data acquired from *in vitro* experiments. (A) SF₂, SF₄, SF₆, and SF₈ ($n = 20$). (B) D₁₀ and D₅₀ ($n = 20$).




Figure 3: CV values of clonogenic survival. In-house, data from in-house experiments. Selected, data from selected publications that employed the following experimental settings: radiation type: X-rays; dose rate: 1.14 ± 0.5 Gy/min; and timing of cell seeding: before irradiation. All, data from all publications. Dotted line indicates CV of 30%.

Table 1: Univariate analysis of the influence of experimental settings on clonogenic survival

Parameter	SF ₂	SF ₄	SF ₆	SF ₈	D ₁₀	D ₅₀
Radiation type*	0.29	0.29	0.29	0.94	0.74	0.85
Dose rate	0.76	0.80	0.62	0.85	0.69	0.66
Timing for cell seeding**	0.06	0.34	0.23	0.23	0.59	0.99

The differences in SF₂, SF₄, SF₆, SF₈, D₁₀, or D₅₀ between different radiation types and between timings of cell seeding were examined by Mann–Whitney *U* test. The correlation of dose rate with SF₂, SF₄, SF₆, SF₈, D₁₀, or D₅₀ was examined by Spearman’s rank correlation test. *P* values are shown. *X-rays vs. γ -rays; **before irradiation vs. after irradiation.

Table 2: Multivariate analysis of the influence of experimental settings on clonogenic survival

Parameter	SF ₂	SF ₄	SF ₆	SF ₈	D ₁₀	D ₅₀
Radiation type*	0.63	0.49	0.57	0.47	0.95	0.34
Dose rate	0.50	0.24	0.69	0.53	0.95	0.77
Timing for cell seeding**	0.04	0.63	0.47	0.24	0.83	0.91

The influence of radiation type, dose rate, and timing of cell seeding on SF₂, SF₄, SF₆, SF₈, D₁₀, or D₅₀ was examined by multiple linear regression. *P* values are shown. *X-rays vs. γ -rays; **before irradiation vs. after irradiation.

DISCUSSION

In this study, we investigated inter-assay precision of clonogenic assays as a measure for radiosensitivity, using in-house and published data on A549, a cell line frequently studied using this method. The CV values of SF₂ and D₁₀ were below 30% for both datasets regardless of experimental settings, indicating that clonogenic assay has acceptable inter-assay precision as a biomarker for tumor radiosensitivity [6, 7]. To the best of our knowledge, this is the first study to examine inter-assay precision of clonogenic assay using a meta-analytic approach. In addition, considering the comprehensive nature of our literature search, the scale of the compiled data represents the maximum amount of available data regarding clonogenic assay of a specific cell line.

To elucidate the biological properties associated with tumor responses to radiation therapy, several groups analyzed the association of radiosensitivity, which they assessed by performing clonogenic assays, with omics data. However, due to the time- and labor-intensiveness of the assay and the cost of purchasing cell lines, the number of cell lines analyzed in a given study has been limited, below a hundred in most cases [8, 9]. The results of this study indicate acceptable inter-assay precision for SF₂ and D₁₀ in clonogenic assay, providing a rationale for combined analysis of multiple published datasets, leading to greater statistical power. Comprehensive correlation analysis using published clonogenic assay data with available omics data, such as gene mutation status and mRNA expression profiles, will contribute to elucidation of robust biological properties associated with tumor radiosensitivity, which will in turn promote the development of precision cancer medicine for radiation therapy.

The influence of experimental settings on radiosensitivity has been extensively investigated over several decades, with various endpoints including the responses of human tissues, animals, and cultured cells [10–12]. However, little solid evidence is available from clonogenic survival assays of human cancer cell lines. The results of this study revealed that radiation type (X-rays or γ -rays) and dose rate do not significantly impact SF₂ and D₁₀ which exhibit acceptable inter-assay precision (i.e., CV <30%) under consistent experimental settings. Although these results do not exclude the possibility that specific treatment settings affect clonogenic survival, we can at least conclude that the inter-assay precision of SF₂ and D₁₀ obtained using diverse radiation types and dose rates is comparable to that obtained using consistent treatment settings when the data are subjected to meta-analysis, as in this study. The results of this study also revealed that the timing of cell seeding significantly influences SF₂. Therefore, theoretically, the data should be stratified by the timing of cell seeding when SF₂ values are subjected to meta-analysis. On the other hand, the CV values for “before irradiation” and “after irradiation” dataset is 19% and 24%, respectively, which is not evidently smaller than that for the entire dataset (21% as shown in Figure 3), indicating that the stratification by the timing of cell seeding is not necessarily beneficial for the improvement of data precision. In addition, from a practical standpoint, the number of papers reporting clonogenic assay results for a given cell line is not always high as that for A549 (Supplementary Figure 1); in such cell lines, stratification by the timing of cell seeding may decrease the amount of data sets available for analysis, which lowers the reliability of the results. Therefore, the stratification by the timing of cell seeding for the meta-analysis of SF₂ may be employed case-by-case considering these things together.

SF₂, an endpoint that has been utilized for radiosensitivity assessment in the clinic more commonly than SF₄, SF₆, and SF₈, had the lowest CV values [2, 10]. These data shed light on the validity of the traditional use of SF₂ for prediction of clinical radiosensitivity, although the mechanisms underlying the smaller CV for SF₂ remain to be elucidated. On the other hand, it is reasonable that CV values for D₁₀ and D₅₀ calculated using surviving fractions at multiple dose points were generally lower than those for the surviving fractions at each dose point. Together, these findings indicate that, among the endpoints for clonogenic assays tested in this study, SF₂ is the best in terms of both inter-assay precision and convenience of data acquisition.

It may be worthy to note that 85% (6/7) of the papers that provided high outliers employed “before irradiation” as the timing of cell seeding, while 100% (3/3) of the papers that provided low outliers employed “after irradiation” (Figure 1D, 1E and Supplementary Table 1); any other specific experimental settings were commonly employed in those papers. Although univariate and multivariate analyses in the present study did not show significant influence of the timing of cell seeding on the survival endpoints other than SF₂, this point should be further pursued in future.

This study has the following limitations. First, no firm consensus has been established regarding the criteria for inter-assay precision for assessment of potential biomarkers. Although we followed the recommendation of the FDA [6, 7], inter-assay precision of clonogenic assay should be further investigated in the future, taking into account other criteria. Secondly, in the literature search, we excluded papers in which cells were irradiated as suspensions, because these represented a small minority of studies (2 of 194 papers reporting clonogenic assay of IR-treated A549 cells). Also, due to the low statistical power, we were not able to analyze the influence of radiation source (e.g., ⁶⁰Co, ¹³⁷Cs, etc.) on clonogenic survival in greater detail. These factors can affect clonogenic survival, and should therefore be investigated in the future. Finally, we analyzed only one cell line; because the results may differ in other cell lines with genetic profiles distinct from those of A549 cells, an analysis using different cell lines should be performed in the future.

In summary, we conducted a comprehensive meta-analysis of in-house and published data on clonogenic assay for IR-treated A549 cells. The results showed that SF₂ and D₁₀ have acceptable inter-assay precision as endpoints for clonogenic survival. These results provide a rationale for the combined analysis of published clonogenic assay data, which may contribute to improvement of precision cancer medicine in radiation therapy by facilitating the discovery of robust biological profiles associated with tumor radiosensitivity.

MATERIALS AND METHODS

Literature search

All published data regarding 1039 human cancer cell lines registered in CCLE, treated with X-rays or γ -rays, were searched using PubMed in April to June of 2016 (Supplementary Figure 1). For each cell line listed in Supplementary Table 3, the search was conducted using the terms “*cell line name* AND (X-rays OR gamma rays OR radiation)”; both *Primary name* and *Aliases* described in Supplementary Table 3 were used for cell line *name*. Publications in languages other than English were excluded. Among the cell lines examined, the three with the most related papers were MCF7, A549, and HepG2 (1509, 1455 and 764 papers, respectively). Two radiation oncologists (EN and TBMP) examined all the manuscripts related to these three cell lines in their entirety, and identified publications containing data obtained from clonogenic assays after treatment with X-rays or γ -rays alone. Papers in which cells were treated with empty vector, siRNA, or reagent vehicles in the setting described as “radiation alone” were excluded because such treatments could potentially influence clonogenic survival. However, papers in which cells were treated with dimethyl sulfoxide (DMSO) in the setting described as “radiation alone” were not excluded, based on the observation that DMSO treatment does not influence clonogenic survival after irradiation (Supplementary Figure 2). Papers in which cells received irradiation in suspension were also excluded.

Acquisition of clonogenic survival data from the literature

From 192 papers listed in Supplementary Table 1, the values for SF₂, SF₄, SF₆, SF₈, D₁₀, and D₅₀ were acquired as the endpoints for clonogenic survival. SF_X indicates the surviving fraction of cells irradiated with X Gy, whereas D_X indicates the radiation dose required for survival of X% [10]. For SF₂, SF₄, SF₆, and SF₈, the values were recorded if they were described in the manuscript or tables; if not, the values were determined by overlaying the electronic figures describing clonogenic survival on grid scales in semi-transparent display. The values were recorded up to two decimal places (Supplementary Figure 3). For the papers in which all values for SF₂, SF₄, SF₆, and SF₈ were available, D₁₀ and D₅₀ were calculated as previously described [13]. Briefly, survival curves were generated by fitting the surviving fraction to a linear-quadratic model: SF = exp(- α D - β D²), where SF is the surviving fraction and D is the dose. Then, the D₁₀ and D₅₀ values were calculated by solving the resulting equations for survivals of 50% and 10%, respectively.

Cell culture

A549 cells were purchased from ATCC and cultured using DMEM (Gibco) supplemented with 10% fetal bovine serum (Sigma).

Clonogenic assay

Clonogenic assay was performed as described previously [1, 13]. Briefly, cells were seeded on 6-well plates in specified numbers in triplicate; 12 hours later, the cells were exposed (or not) to X-ray irradiation (2, 4, 6, or 8 Gy) using a Faxitron RX-650 radiation source (100 kVp, 1.14 Gy/min; Faxitron Bioptics). After incubation for an additional 10 days, the cells were fixed with methanol and stained with crystal violet. Colonies of at least 50 cells were counted. The surviving fractions at 2, 4, 6, and 8 Gy were normalized to the corresponding unirradiated controls, yielding SF₂, SF₄, SF₆, SF₈, respectively. The values for D₁₀ and D₅₀ were acquired as described in *Acquisition of clonogenic survival data from the literature*, above. The average values for each clonogenic survival endpoint were used for subsequent analyses.

Statistical analysis

Radiation type (i.e., X-rays and γ -rays) and the timing of cell seeding (i.e., before or after irradiation) were analyzed as categorical variables. Dose rate, SF₂, SF₄, SF₆, SF₈, D₅₀, and D₁₀ were analyzed as continuous variables. The differences in SF₂, SF₄, SF₆, SF₈, D₁₀, or D₅₀ between different radiation types and between the timings of cell seeding were examined by Mann–Whitney *U* test. The correlation of dose rate with SF₂, SF₄, SF₆, SF₈, D₁₀, or D₅₀ was examined by Spearman's rank correlation test. The influence of radiation type, dose rate, and the timing of cell seeding on SF₂, SF₄, SF₆, SF₈, D₁₀, or D₅₀ was examined by multivariate analysis using multiple linear regression. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, ver. 3.3.2) [14]. Differences were considered statistically significant at *P* values < 0.05.

Abbreviations

CCLC, Cancer Cell Line Encyclopedia; CV, coefficient of variation; DMSO, dimethyl sulfoxide; FDA, Food and Drug Administration; IR, ionizing radiation.

Author contributions

EN, TBMP, and TO conducted the literature search and *in vitro* experiments, and wrote the manuscript. EN,

TBMP, and KS analyzed the data. TO contributed to data interpretation and takes responsibility for all the analyzed data. TN supervised study concept. All authors read and approved the manuscript. EN and TBMP contributed equally to this work.

ACKNOWLEDGMENTS

We thank Dr. Hiro Sato and Ms. Yuka Hirota of Gunma University for technical assistance.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

FUNDING

This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan for programs for Leading Graduate Schools, Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering. This work was also supported by Grants-in-Aid from the Japan Society for the Promotion of Science for KAKENHI.

REFERENCES

1. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells *in vitro*. *Nat Protoc*. 2006; 2:2315–9. <https://doi.org/10.1038/nprot.2006.339>
2. Torres-Roca JF. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. *Per Med*. 2012; 2:547–57. <https://doi.org/10.2217/pme.12.55>
3. Hinkson IV, Davidsen TM, Klemm JD, Kerlavage AR, Kibbe WA. A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine. *Front Cell Dev Biol*. 2017; 2:83. <https://doi.org/10.3389/fcell.2017.00083>.
4. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*. 2012; 2:603–7. <https://doi.org/10.1038/nature11003>.
5. Website for Catalogue of Somatic Mutations in Cancer. <http://cancer.sanger.ac.uk/cosmic>
6. Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS, Shockcor J, Loftus N, Holmes E, Nicholson JK. Global metabolic profiling of animal and human tissues via UPLC-MS. *Nat Protoc*. 2013; 2:17–32. <https://doi.org/10.1038/nprot.2012.135>.
7. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, Shockcor J, Holmes E, Nicholson JK. Global metabolic

- profiling procedures for urine using UPLC-MS. *Nat Protoc.* 2010; 2:1005–18. <https://doi.org/10.1038/nprot.2010.50>.
8. Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. *Int J Radiat Oncol Biol Phys.* 2009; 2:489–96. <https://doi.org/10.1016/j.ijrobp.2009.06.014>.
 9. Kim HS, Kim SC, Kim SJ, Park CH, Jeung HC, Kim YB, Ahn JB, Chung HC, Rha SY. Identification of a radiosensitivity signature using integrative meta analysis of published microarray data for NCI-60 cancer cells. *BMC Genomics.* 2012; 2:348. <https://doi.org/10.1186/1471-2164-13-348>.
 10. Hall EJ, Giaccia AJ. *Radiobiology for the Radiologist*, 6th edition. Lippincott Williams & Wilkins, Philadelphia, PA, 2006.
 11. Humphrey RM, Sinclair WK. The relative biological effectiveness of 22-Mevp X-rays, Cobalt-60 gamma rays, and 200 kvcp X-rays. VIII. Determined by the growth capacity of tumor cells *in vitro*. *Radiat Res.* 1963; 2:593–9.
 12. Winzel E, van der Merwe EJ, Groenewald W, Pistorius S, Slabbert JP, Robinson L, Böhm L. The relative biological effectiveness of 100 kV X-rays determined by the V-79 cell colony assay. *S Afr Med J.* 1987; 2:693–5.
 13. Oike T, Ogiwara H, Torikai K, Nakano T, Yokota J, Kohno T. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining. *Int J Radiat Oncol Biol Phys.* 2012; 2:815–21. <https://doi.org/10.1016/j.ijrobp.2012.01.017>.
 14. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant.* 2013; 2:452–8. <https://doi.org/10.1038/bmt.2012.244>.